Maxim Pharmaceuticals Announces Robert L. Zerbe Nominated to Its Board of Directors
Maxim Pharmaceuticals, Inc. announced that it has nominated Robert L. Zerbe, M.D. to serve as an independent member of its Board of Directors.
Dr. Zerbe, 52, is the Chief Executive Officer and Founder of QuantRx Pharmaceuticals, a private biopharmaceutical company. Until 2000, Dr. Zerbe was employed by Pfizer as its Senior Vice President of Global Research and Development and Director of Development Operations. Dr. Zerbe also held senior positions in pharmaceutical development at Warner-Lambert and Eli Lilly. During his career in the United States and Europe, Dr. Zerbe has been involved in leadership of the development of a number of the biggest and most successful pharmaceutical drugs, including Prozac(R), Lipitor(R), Neurontin(R), Humulin(R), Humatrope(R), Zyprexa(R), Raloxifene(R), Humalog(R), and Gemzar(R).
Dr. Zerbe is a physician licensed in Indiana and Michigan with training in Internal Medicine and Endocrinology at Indiana University and advanced training in Neuroendocrinology at the National Institute of Mental Health. Dr. Zerbe earned his M.D. with distinction at the Indiana University School of Medicine in Indianapolis. He is the author of numerous research publications in endocrinology, neuroendocrinology and pharmacology, and has significant experience in clinical research and development, clinical trial design and management, and regulatory affairs.
Most read news
Topics
Organizations
Other news from the department people

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.